


02-16-06

IFW-H



PC25603A
Supplemental Information Disclosure Statement For Appln. No.
10/718,337

Certificate of Mailing (37 C.F.R. §1.8):

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (EV 615409314 US) in an envelope addressed to: Mail Stop: Amendments Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on this 15th day of February 2006.

Pamela Hollander
Pamela Hollander

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
Allen BORCHARDT, et al.

Group Art Unit: **1625**

Serial No.: **10/718,337**

Examiner: **Amelia A. Owens**

Confirmation No.: **9247**

Filed: **November 19, 2003**

For: **INHIBITORS OF HEPATITIS C VIRUS
RNA-DEPENDENT RNA POLYMERASE,
AND COMPOSITIONS AND TREATMENTS
USING THE SAME**

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith are the following documents:

- | | |
|---|-------------------|
| 1. Transmittal Letter | 1 page; |
| 2. Transmittal of Supplemental Information Disclosure Statement | 2 pages; |
| 3. PTO.SB/08A & B | 1 page; |
| 4. Copies of Cited Reference | 3 references; and |
| 5. Fee Due | Deposit Account. |

Respectfully submitted,


Date: February 15, 2006

Jeffrey H. Tidwell
Jeffrey H. Tidwell
Attorney for Applicant
Registration No. 47,995

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 638-3877
Fax: (858) 678-8233

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/718,337
Filing Date	11/19/2003
First Named Inventor	Allen BORCHARDT
Art Unit	1625
Examiner Name	A.A. Owens
Attorney Docket Number	PC25603A

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	DOCUMENT NUMBER Number-Kind Code ²	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	GADJA, C., et al. "An Efficient Asymmetric Synthesis of Lead Dihydropyrene HIV Protease Inhibitors," <i>Abstracts of Papers, 37th Interscience Conference on Antimicrobial Agents and Chemotherapy</i> , Toronto, Canada, September 1997, Abstr. 1-199b.	
	AB	KÜNSTLINGER, M., "Triazolo[1,5- α]- und -[4,3- α]pyrimidine aus 3-Alkoxyacroleinen und 3 Amino-1,2,4-triazolen," <i>Communications, Synthesis</i> , January 1983, p. 44-47	
	AC	TAIT, B.D., "4-Hydroxy-5, 6-dihydropyrones. 2. Potent Non-Peptide Inhibitors of HIV Protease," <i>J. Med. Chem.</i> , 1997, 3781-3792, vol. 40.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Information Disclosure Statement

Submitted: February 15, 2006, EV 615409314 US

Page 1 of 2



PC25603A
Supplemental Information Disclosure Statement For Appln. No.
10/718,337

Certificate of Mailing (37 C.F.R. §1.8):
I hereby certify that this correspondence is being
deposited with the United States Postal Service as
Express Mail (EV 615409314 US) in an envelope
addressed to: Mail Stop: **Amendments**
Commissioner for Patents, PO Box 1450, Alexandria,
VA 22313-1450, on this **15th day of February 2006**.

s/ Pamela Hollander
Pamela Hollander

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
Allen BORCHARDT, et al.

Group Art Unit: **1625**

Serial No.: **10/718,337**

Examiner: **Amelia A. Owens**

Confirmation No.: **9247**

Filed: **November 19, 2003**

For: **INHIBITORS OF HEPATITIS C VIRUS
RNA-DEPENDENT RNA POLYMERASE,
AND COMPOSITIONS AND TREATMENTS
USING THE SAME**

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b) or 1.97(c)

37 CFR § 1.97(b)

- ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

37 CFR § 1.97(c)

- ☒ The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of (1) a Final Action under § 1.113; (2) a Notice of Allowance under § 1.311; or (3) an action that otherwise closes prosecution in the application. The Commissioner is hereby authorized to charge the fee as set forth in § 1.17(p) to Deposit Account Number 500329.

02/17/2006 EFLORES 00000112 500329 10718337

01 FC:1806 180.00 DA

- ☒ Applicant requests that the Examiner consider the following copending applications:


Application Serial No.	Filing Date	Atty. Docket No.
11/204,269	08/15/2005	PC32310A

- ☐ Copies of these copending applications are enclosed.
- ☒ Applicant hereby requests consideration of the Information Disclosure Statement, USPTO form 1449, submitted herewith. Copies of the cited references, except as noted below, are enclosed.
- ☐ This application is a continuation, divisional or continuation-in-part of Serial No. [REDACTED]. Copies of the cited references, if not enclosed, are available in the file of the parent application or parents thereof.
- ☐ Copies of U.S. Patents and U.S. Patent Application Publications are not enclosed. (waiver of 37 CFR 1.98(a)(2)(iii) pursuant to 37 CFR 1.183).
- ☐ Applicant hereby requests consideration of the enclosed International Search Report, which was received in a related international patent application.

The Commissioner is hereby authorized to charge any fee deficiency, including any fee required under 37 C.F.R. § 1.17(p), or credit any overpayment, to Deposit Account Number 500329. A duplicate copy of this form is enclosed.

Respectfully submitted,

Date: February 15, 2006



Jeffrey H. Tidwell
Attorney for Applicant
Registration No. 47,995

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 638-3877
Fax: (858) 678-8233